17 results on '"Moatti, Jean-Paul"'
Search Results
2. Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon data from the STRATALL ANRS 12110/ESTHER trial
- Author
-
Ndziessi, G., Cohen, J., Kouanfack, C., Boyer, S., Moatti, Jean-Paul, Marcellin, F., Laurent, Christian, Spire, B., Delaporte, Eric, Carrieri, M.P., and 1ANRSAgence Nationale de Recherche sur le Sida3ESTHER Study Group4Paris5FRA (ed.)
- Subjects
AIDS ,behaviors ,Sub-Saharan Africa ,sexual risk ,antiretroviral therapy ,sexual activity ,HIV ,Cameroon - Abstract
The continued scaling-up of antiretroviral therapy (ART) in Sub-Saharan Africa provides an opportunity to further study its impact on sexual behaviors among people living with HIV/AIDS (PLWHA). We explored time trend and correlates of sexual activity among PLWHA initiating ART in Cameroon and compared sexual risk behaviors between patients sexually active before and after initiating ART and those resuming sexual activity after ART initiation. Analyses were based on longitudinal data collected within the randomized trial (n = 459) conducted in nine rural district hospitals in Cameroon. Sexual activity was defined as reporting at least one sexual partner during the previous 3 months. Inconsistent condom use (ICU) was defined as reporting to have never, sometimes, or nearly always used condoms at least once with a partner(s) either HIV-negative or of unknown HIV status during the same period. Mc Nemar tests were used to assess time trend, while mixed-effect logistic regressions were conducted to analyze the effect of time since ART initiation on sexual activity. The proportion of sexually active patients significantly increased over time: from 31.8% at baseline to 40.2 and 47.1% after 6 and 12 months of ART, respectively (p=0.001), to 55.9% after 24 months (p=0.02). After adjustment for behavioral and psychosocial factors, time since ART initiation was independently associated with reporting sexual activity (AOR [95% CI] = 1.30 [1.171.46] per 6-month increase, p=0.001). ICU was more frequent among patients sexually active both before and after ART initiation than among those who resumed sexual activity after ART initiation (82 vs. 59%, p
- Published
- 2013
3. Economie de la santé dans les pays en développement : ce que la lutte contre le sida a changé = The economics of health care in developing countries : what the fight against the AIDS epidemics has changed
- Author
-
Moatti, Jean-Paul
- Subjects
AIDS ,Macroeconomic growth ,Infectious diseases ,Health care finance ,Health care systems ,health care economics and organizations ,Developing countries - Abstract
Since the start of the new century, development aid targeted on health care has seen an unprecedented rise, driven by the fight against AIDS. This article shows how this struggle has been accompanied with a renewal of the economic paradigms governing international action in favour of health care in developing countries: the idea that an improvement in health care constitutes an unavoidable prerequisite to macroeconomic growth, rather than a consequence; the insistence on the founding of mechanisms for health insurance to finance the costs of health care, rather than covering the costs at the point of use by the health care users; a concern to impose price differentials for access to medicine in developing countries, and to introduce flexibility in the regulation of international intellectual property law; the priority to vertical programmes targeted on certain illnesses, thought to act as levers for a global reinforcement of health care systems. This article discusses the pertinence of these new paradigms in light of the evolution of the AIDS/HIV epidemic, and the international context. To cite this article: J.R Moatti, C R. Biologies 331 (2008).
- Published
- 2008
4. Financing efficient HIV care and antiretroviral treatment to mitigate the impact of the AIDS epidemic on economic and human development
- Author
-
Moatti, Jean-Paul, Barnett, Tony, Souteyrand, Yves, Flori, Yves-Antoine, Dumoulin, Jérôme, Coriat, Benjamin, Laboratoire d'Economie de la Production et de l'Intégration Internationale (LEPII), Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF), Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.A., Ciesla, Catherine, and Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.A.
- Subjects
AIDS ,médicament ,financement ,efficacité ,treatment ,SIDA ,Pays en Voie de Développement ,drug ,developing countries ,[SHS.ECO] Humanities and Social Sciences/Economics and Finance ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,coût ,traitement médical - Abstract
This text presents the second part of the book. In the first two decades of the HIV Epidemic, the strategy in developing world was focused on preventive methods. The challlenge is now give HIV treatment access for the benefit of People Living With HIV/Aids (PLWH) and for curbing the epidemic. Experiences in Brazil, Chile, Thailand are implemented to achieve this goal. In some African countries as Cote d'Ivoire, Senegal and Uganda, pilot projects have proved the feasibility and efficency of Antiretroviral treatments in subsaharian countries. These experiences show that a strong involvement of governments to promote or to regulate the delivery of ARV drugs is needed to face an eventual "antiretroviral anarchy". Scaling up access to ART will often take place in a context of failing government systems. The economic arguments against access to HIV treatment in developing countries are critically reviewed and the book brings evidence that treatment is rational as economic decision. Furthermore, the books stands the economic impact of the epidemic is underestimated with a new conceptual approach which highlights the "involution trap" where countries can fall in the long run. Some "optimistic" results of previous models, as a reduced pressure on land and capital, are artefacts. So the main rationale of HIV Treatment is to prevent falling in this trap : more resources must be allocated to scaling up programs. The book shows how countries can mobilize new resources. Every country must find the best balance between public subsidies, private insurance, private fundings and patients participation., Ce texte présente la seconde partie du livre. Dans les deux premières décennies de l'épidémie Sida, la stratégie dans les pays en développement a été centrée sur les méthodes préventives. Le défi maintenant est de permettre l'accès au traitement pour les personnes vivant avec le VIH/SIDA et pour ralentir l'épidémie. Les expériences du Brésil, du Chili, de la Thaïlande ont été réalisées dans ce but. Dans certains pays africains comme la Côte d'Ivoire, le Sénégal, l'Ouganda, des projets pilotes ont démontré la faisabilité et l'efficacité du traitement ARV dans les pays sub-sahariens. Ces expériences montrent qu'un fort engagement des gouvernements pour promouvoir ou réglementer la distribution des médicaments ARV est nécessaire pour éviter une éventuelle "anarchie d'antirétroviraux". La montée en puissance de l'accès à ces traitements se situera souvent dans un contexte de systèmes publics défaillants. Les arguments économiques contre le traitement du sida sont examinés et critiqués, et le livre apporte les preuves que le traitement est une décision économique rationnelle. En outre, le livre soutient la thèse que l'impact économique de l'épidémie a été sous-évalué, avec une approche conceptuelle nouvelle qui souligne le piège d'effondrement dans lequel les pays peuvent tomber à long terme. Certains résultats "optimistes" dans les modèles antérieurs, comme une réduction de la pression sur la terre et sur le capital, sont des artefacts. Il en résulte que le principal argument en faveur du traitement par ARV est de prévenir ce piège : plus de ressources doivent être allouées au passage à l'échelle des programmes. Le livre montre comment les pays peuvent mobiliser de nouvelles ressources : chaque pays doit trouver le meilleur équilibre pour lui entre des financements publics, l'assurance privés, des donations privées et la participation des patients.
- Published
- 2003
5. Economics of AIDS and access to HIV/AIDS care in developing countries : issues and challenges
- Author
-
Moatti, Jean-Paul, Coriat, Benjamin, Souteyrand, Yves, Barnett, Tony, Dumoulin, Jérôme, Flori, Yves-Antoine, Laboratoire d'Economie de la Production et de l'Intégration Internationale (LEPII), and Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)
- Subjects
médicament ,SIDA ,antiretroviral ,Pays en Voie de Développement ,drug ,developing countries ,Thailand ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,price ,Brésil ,AIDS ,brevet ,patent ,Thaïlande ,prix ,Brazil ,traitement médical - Abstract
486 p.; This book collects studies performed mainly with the support of the Agence Nationale de Recherche contre le Sida (French French National Agency of Research against AIDS). The purpose is to analyse the conditions to improve access to drugs against AIDS in developing countries, to urge on international agencies determinedly support patients treatment. The first part deals with the market of antiretrovirals and patents : How the prices drop taked place in 1998-2002, what were the debates about Intellectual Property Rights and WTO, what happened in countries as Brazil and Thailand ? The second part deals with the impact of AIDS epidemic in the developing world and the role of therapeutic strategies to lower this impact. The book backs up the argument that the impact has been undersestimated and theses strategies are feasible.; Cet ouvrage réunit des travaux effectués principalement dans le cadre de l'Agence Nationale de Recherche contre le Sida. Il a pour objectif d'analyser les conditions de l'amélioration de l'accès aux médicaments traitant le Sida dans les pays en développement pour que les pays et les agences internationales s'engagent résolument dans le traitement des malades. La première partie traite du marché des antirétroviraux et de la question des brevets : comment s'est passé la baisse des prix dans les années 1998-2002, quels ont été les débats à propos de la protection des brevets et de l'OMC, que s'est-il passé dans des pays-phares comme le Brésil ou la Thailande ? La seconde partie porte sur l'impact du Sida dans les pays en développement et le rôle de stratégies thérapeutiques pour réduire cet impact. La thèse soutenue est que cet impact a été sous-évalué et que des stratégies sont possibles.
- Published
- 2003
6. Patents, generic drugs and the markets for antiretrovirals
- Author
-
Coriat, Benjamin, Dumoulin, Jérôme, Flori, Yves-Antoine, Barnett, Tony, Souteyrand, Yves, Moatti, Jean-Paul, Laboratoire d'Economie de la Production et de l'Intégration Internationale (LEPII), Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF), Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.A., Ciesla, Catherine, and Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.A.
- Subjects
médicament ,SIDA ,drug ,Thailand ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,price ,Brésil ,AIDS ,brevet ,patent ,generic drug ,médicament générique ,Thaïlande ,[SHS.ECO] Humanities and Social Sciences/Economics and Finance ,prix ,Brazil ,traitement médical - Abstract
In 1994, the Uruguay Round culminated by the creation of WTO which extends worldwhile patent protection for new products, including drugs. In 1996, an efficent Aids treatment was available in the world market : antiretroviral combined therapy. The coexistence of these two series of events is obviously coincidal, but has fueled intensive debates about their conflictual interaction. A focus is made on the growing tension between the dimension of the collective good of public health and profit-seeking by private firms involved in that domain. The TRIPS Agreement, part of WTO has generated new constraints to face to AIDS epidemic and other public health issues as well.Thailand and Brazil succeeded to manufacture generic drug for the benefit of domestic patients through many international obstacles. A special chapter is devoted to the prices : how are they determined ? how have the main protagosnists in this field been behaving? What can we expect in the future ?, En 1994, l'Uruguay Round s'est achevé avec la création de l'OMC qui étend au monde entier la protection par brevet des innovations, et en particulier des nouveaux médicaments. En 1996, apparaît sur le marché mondial un nouveau traitement du Sida : la trithérapie par ARV. La coïncidence de ces deux séries d'événements est évidemment une coïncidence, mais a alimenté d'intenses débats sur leurs interactions conflictuelles. Est analysée la tension croissante entre la dimension de bien collectif qu'est la santé publique et la recherche du profit par les firmes engagées dans ce domaine. L'accord ADPIC, partie de l'OMC, a créé de nouvelles contraintes pour lutter contre le Sida, et d'autres problèmes de santé publique. La Thaïlande et le Brésil on réussi à fabriquer des médicaments génériques pour traiter les malades de ces pays malgré de nombreux obstacles internationaux. Ce chapitre est consacré aux prix : comment sont-ils déterminés, comment se sont comportés les principaux protagonistes, que pouvons nous attendre dans l'avenir ?
- Published
- 2003
7. Chapter 15: The normalisation of AIDS policies in Europe.
- Author
-
Steffen, Monika, Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
HEALTH policy ,AIDS ,PUBLIC health ,PUBLIC administration ,POLICY sciences ,HUMAN services - Abstract
This chapter examines the factors shaping the development of AIDS policies in several European countries, including France, Great Britain, Italy and Germany. Normalisation describes the integration of the AIDS issue into existing agendas, priorities and networks of public policies, in particular health and welfare policies. The process endows the newly introduced policies with long-term sustainability. Normalisation is a dynamic process, combining the path dependency of health policy and AIDS-rooted innovations. It has proved to be more complex and laden with conflicts in countries that were poorly equipped for public health management and, therefore, opposed to the recognition and the practical treatment of the new public health risks. Far-reaching consequences can be expected, particularly in these countries, because the epidemic contributes to the consolidation of the poorly established parts of the public health sector. This calls into question elements of the political culture, like the boundary between what can be considered public and private rights or responsibilities. Collective norms have had to undergo changes, which explains the existence of political controversy in many countries.
- Published
- 2000
8. Chapter 11: Risk behaviour and HIV infection in European prisons.
- Author
-
Rotily, Michel, Weilandt, Caren, Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
AIDS ,HIV infections ,EPIDEMIOLOGY ,PRISONERS ,INFECTIOUS disease transmission ,INTRAVENOUS drug abusers ,DRUG abusers - Abstract
This chapter deals with the issue of the epidemiology of HIV/AIDS in prisons in Europe. The analysis shows that European health and prison administrations are concerned with the issue of HIV/AIDS in prison, and improvements in prevention policy have already been achieved. However, all published data highlight the frequency of risk behaviour among prisoners, before, during and after incarceration, and the inadequacies of current prevention policy. Access to harm reduction measures in European prisons still falls short of the World Health Organisation's 1993 Guidelines on HIV Infection and AIDS in Prisons. This situation presents public health and penitentiary administrations with a tremendous challenge to provide much-needed educational, prevention and treatment services. Although it has been shown that prevention strategies aimed only at eliminating drug use are inadequate among injecting drug users living in the community, there is still a tendency in European prisons to adhere to this old belief. Debates about harm reduction in prison are not broad enough, and are less advanced than those held by people in general. Such debate is crucial. Prisoners are part of the community, and they come from and return to the community. They deserve the same level of information, protection and care received by people outside prison. Communicable diseases in prisons should be considered as a general public health issue and not one restricted to this subgroup of the population.
- Published
- 2000
9. Chapter 10: Young people, social relationships and sexuality in Bulgaria.
- Author
-
Vassileva, Biliana, Komarova, Milana, Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
INTERPERSONAL communication ,INTERPERSONAL relations ,AIDS ,HIV infections ,RISK-taking behavior ,HUMAN behavior ,YOUTH psychology - Abstract
This chapter examines whether problems in communication increased young people's vulnerability to HIV and AIDS and risk behaviour in Bulgaria. Communication with parents was often perceived as a violation of the young person's own personality, because most of the time parents' knowledge (including their norms and values) served as a base for judgements and comparisons. The consequence was a self-limited form of communication, because adolescents felt they knew what would be the reaction of their parents. Didactic ways of transferring knowledge from parents to children were seen as preventing young people gaining their own experience. As regards help, parents are kept on standby in case problems arose that could not be solved either by the young people themselves, or by friends. Young people talked about sex spontaneously with their friends in almost all of the groups, with the exception of the youngest group of girls. When asked, respondents said that they talked about sex a lot. In young people's eyes, sexually transmitted infections, including HIV/AIDS, are not a major concern. The decision to engage in sex is mainly influenced by group norms that are quite different from those of the older generation and are shaped by a feeling of liberation from outdated values and norms. At the same time, however, these norms are linked to fears that the system to which this behaviour is a reaction that may sanction them.
- Published
- 2000
10. Introduction.
- Author
-
Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
AIDS ,MEDICAL research ,DRUG abuse ,DRUGS of abuse - Abstract
This article introduces the studies included in the book, AIDS in Europe: New Challenges for the Social Sciences. The contributions in this book represent some of the most important attempts by European social scientists to engage with recent changes in the epidemic. All the papers in this book were initially presented at the 2nd European Conference on the Methods and Results of Social and Behavioural Research on AIDS (New Challenges for Social and Behavioural Science) organised in January 1998. While much earlier HIV and AIDS-related social and behavioural research focused on issues related to prevention and collective and individual behaviour change, recent developments have made studies of the impact of new treatments on HIV care, and of the experience of people living with HIV, a priority. Innovative studies linked to the themes of Living with HIV and therapeutic advances are therefore presented in the first part of the book. Another part of the book is devoted to the issue of drug use: user and policy perspectives. It is a well-established fact that HIV-infected injecting drug users tend to have poorer access to medical care, and especially to antiretroviral treatment, than other groups, even in European countries where free or low-cost public sector care is available. It is also clear that drug users are especially vulnerable to the cumulative effects of various sources of inequality. This vulnerability is of course exacerbated by the illegal character of drug use in all European countries which exposes active drug users to a high risk of imprisonment.
- Published
- 2000
11. Modeling HIV/AIDS Drug Price Determinants in Brazil: Is Generic Competition a Myth?
- Author
-
Meiners, Constance, Sagaon-Teyssier, Luis, Hasenclever, Lia, and Moatti, Jean-Paul
- Subjects
HIV infections ,AIDS ,DRUG prices ,GENERIC drugs ,ECONOMIC competition ,DEVELOPING countries - Abstract
Background: Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatment, with antiretroviral drugs (ARVs) being delivered to nearly 190,000 patients. The analysis of ARV price evolution and market dynamics in Brazil can help anticipate issues soon to afflict other developing countries, as the 2010 revision of the World Health Organization guidelines shifts demand towards more expensive treatments, and, at the same time, current evolution of international legislation and trade agreements on intellectual property rights may reduce availability of generic drugs for HIV care. Methods and Findings: Our analyses are based on effective prices paid for ARV procurement in Brazil between 1996 and 2009. Data panel structure was exploited to gather ex-ante and ex-post information and address various sources of statistical bias. In-difference estimation offered in-depth information on ARV market characteristics which significantly influence prices. Although overall ARV prices follow a declining trend, changing characteristics in the generic segment help explain recent increase in generic ARV prices. Our results show that generic suppliers are more likely to respond to factors influencing demand size and market competition, while originator suppliers tend to set prices strategically to offset compulsory licensing threats and generic competition. Significance: In order to guarantee the long term sustainability of access to antiretroviral treatment, our findings highlight the importance of preserving and stimulating generic market dynamics to sustain developing countries' bargaining power in price negotiations undertaken with originator companies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
12. Économie de la santé dans les pays en développement : ce que la lutte contre le sida a changé
- Author
-
Moatti, Jean Paul
- Subjects
- *
MEDICAL care , *AIDS , *ECONOMIC development , *HEALTH insurance , *HEALTH promotion , *PUBLIC health ,DEVELOPING countries - Abstract
Abstract: Since the start of the new century, development aid targeted on health care has seen an unprecedented rise, driven by the fight against AIDS. This article shows how this struggle has been accompanied with a renewal of the economic paradigms governing international action in favour of health care in developing countries: the idea that an improvement in health care constitutes an unavoidable prerequisite to macroeconomic growth, rather than a consequence; the insistence on the founding of mechanisms for health insurance to finance the costs of health care, rather than covering the costs at the point of use by the health care users; a concern to impose price differentials for access to medicine in developing countries, and to introduce flexibility in the regulation of international intellectual property law; the priority to vertical programmes targeted on certain illnesses, thought to act as levers for a global reinforcement of health care systems. This article discusses the pertinence of these new paradigms in light of the evolution of the AIDS/HIV epidemic, and the international context. To cite this article: J.P. Moatti, C. R. Biologies 331 (2008). [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
13. Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning
- Author
-
Lasserre, Pierre, Moatti, Jean-Paul, and Soubeyran, Antoine
- Subjects
- *
HIV , *AIDS , *ANTIRETROVIRAL agents , *VIRUS inhibitors , *UNCERTAINTY , *MEDICAL care - Abstract
Abstract: Criteria for initiation of highly active antiretroviral treatments (HAART) in HIV-infected patients remain a matter of debate world-wide because short-term benefits have to be balanced with costs of these therapies, and restrictions placed on future treatment options if resistant viral strains develop. On the other hand, postponing the introduction of HAART may involve a therapeutic opportunity cost if a patient’s health is allowed to deteriorate to such an extent of becoming unable to benefit from new treatments currently under development when they become available. We introduce a two period model where period one treatment adoption is an irreversible act with future, but uncertain, consequences. New information, both endogenous and exogenous, arises over time and shapes the conditions surrounding the second period therapeutic decision. A surprising result is that, under conditions that appear close to those surrounding the HAART debate, the magnitude of the feared resistance effect has no effect on leaves the optimal treatment decision as far as it is high enough. JEL classification: I18; C61 Keywords: Therapeutic decisions; Uncertainty; Information; Irreversibility; Treatment Résumé Le bien-fondé d’administrer précocement des traitements antiré troviraux à haute activité (HAART) aux personnes infectées par le VIH reste objet de débats dans le monde car leurs bienfaits à court terme peuvent compromettre les traitements futurs si se dé veloppent des souches résistantes du virus. Par ailleurs retarder le recours aux HAART comporte un coût d’opportunité thérapeutique si la santé du patient se dégrade au point qu’il ne peut plus bén éficier par la suite des traitements encore en cours de dé veloppement. Nous formulons un modèle à deux périodes où l’adoption du traitement de première période est irréversible et engage le futur, alors que des informations et connaissances nouvelles, exog ènes et endogènes, déterminent les conditions entourant la dé cision thérapeutique de deuxième période. Paradoxalement, sous des conditions reflètant bien les enjeux du recours aux HAART, il s’av ère que l’effet résistance éventuel a d’autant moins de chance d’importer pour la décision optimale, que sa gravité est élev ée. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
14. Determinants of Condom Use among French Heterosexuals with Multiple Partners.
- Author
-
Moatti, Jean-Paul, Bajos, Nathalie, Durbec, Jean-Pierre, Menard, Collette, and Serrand, caroline
- Subjects
- *
HIV , *SEX customs , *HIV infection transmission , *AIDS , *SEXUALLY transmitted diseases , *CONDOM use , *HUMAN sexuality , *MULTIVARIATE analysis , *CONTRACEPTION - Abstract
In September 1988, a sample of French individuals between 18 and 49 years of age, who reported more than one sexual partner in the past six months and who considered themselves heterosexuals (n = 1088), were interviewed at home about risk perception of human immunodeficiency virus (HIV) transmission, sexual behavior, and condom use. Systematic or occasional use of condoms during the previous 12 months was reported by 46.9 percent of respondents. Among condom users, 38.7 percent declared they had never used condoms before the last 12 months, fear of acquired immunodeficiency syndrome (AIDS) rather than contraception being the main motivation of these recent users. Multivariate analysis indicates that voluntary testing for HIV, average or more than average fear of sexually transmitted diseases (STDs), and knowledge of HIV carrier in personal relations are associated with condom use. [ABSTRACT FROM AUTHOR]
- Published
- 1991
- Full Text
- View/download PDF
15. Acknowledgements.
- Author
-
Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
AIDS - Abstract
Presents acknowledgments in line with the publication of the book "AIDS in Europe: New Challenges for the Social Sciences," edited by Jean-Paul Moatti, Yves Souteyrand, Annick Prieur, Theo Sandfort and Peter Aggleton.
- Published
- 2000
16. AIDS in Europe.
- Author
-
Moatti, Jean-Paul, Souteyrand, Yves, Prieur, Annick, Sandfort, Theo, and Aggleton, Peter
- Subjects
AIDS ,EPIDEMICS ,COMMUNICABLE diseases ,HIV infections ,IMMUNOLOGICAL deficiency syndromes ,MEDICAL research - Abstract
This article provides an overview of the book AIDS in Europe: New Challenges for the Social Sciences edited by Jean-Paul Moatti, Yves Souteyrand, Annick Prieur, Theo Sandfort and Peter Aggleton. Major changes in the nature and dynamics of the AIDS epidemic over the last few years are reflected in changing epidemiological trends as well as in the progress made by biomedical research and treatment. AIDS in Europe brings together papers from leading social science researchers to look at the opportunities and challenges these changes bring in their wake and the different ways in which they are being responded to in both Western and Eastern Europe. Four main topics are covered: living with HIV and therapeutic advances, new perspectives on sexuality, drug use--user and policy perspectives and accounting for the epidemic. AIDS in Europe provides a comprehensive overview of current social and behavioural research on HIV and AIDS for all health professionals.
- Published
- 2000
17. Les CDAGS, Bout de chaîne et premier maillon dans le dispositif de prévention contre le Sida
- Author
-
Vernazza-Licht, Nicole, Boiron, Frédérique, Études des Structures, des Processus d’Adaptation et des Changements de l’Espace (ESPACE ), Université de la Méditerranée - Aix-Marseille 2-Université de Provence - Aix-Marseille 1-Avignon Université (AU)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nice Sophia-Antipolis (UNSA), Aix-Marseille Université - Faculté de droit et de science politique (AMU FDSP), Aix Marseille Université (AMU), Moatti jean Paul, Aix-Marseille Université - Faculté de droit et de science politique (AMU DSP), and VERNAZZA, Nicole
- Subjects
Risk ,[SHS.ANTHRO-SE] Humanities and Social Sciences/Social Anthropology and ethnology ,SIDA ,dépistage ,health ,[SHS.ANTHRO-SE]Humanities and Social Sciences/Social Anthropology and ethnology ,Anthropologie ,AIDS ,évenements de vie ,risque ,anthropology ,vulnérabilité ,santé ,CDAGS - Abstract
National audience; L'article s'appuie sur une recherche anthropologique menée dans les centres de dépistage anonyme et gratuit du SIDA à Marseille en 1990. Les auteurs montrent que les stratégies de dépistage s'organisent à partir d’événements de vie puis se recroisent avec des informations médiatiques ou médicales. L'intérêt de mieux connaitre les évènements de vie déclenchant la vulnérabilité psychologique au risque semble évident pour atteindre une meilleure efficacité vis à vis des personnes à risque d'infection par le VIH.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.